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THE OPIOID CRISIS IN THE WORKPLACE:  
WHAT EMPLOYERS MUST DO TO ENSURE  
ANTI-DISCRIMINATION COMPLIANCE AND  
TO SUPPORT THEIR EMPLOYEES 
Jamie Campisi* 
I. INTRODUCTION 
The United States is facing a severe opioid1 crisis with widespread 
consequences affecting every segment of the population.  According to the 
Centers for Disease Control and Prevention, from 1999 to 2016, more than 
350,000 people died in the United States from an opioid overdose.2  More 
specificially, over 200,000 people died from prescription opioid overdoses 
between 1999 and 2017.3  According to the 2016 National Survey on Drug 
Use and Health, 11.5 million Americans misused prescription opioids in 
2016 alone.4  These statistics reflect just some of the reasons why President 
Trump and the United States Department of Health and Human Services 
declared the opioid crisis a nationwide public health emergency on October 
26, 2017.5 
 
* J.D. Candidate, Seton Hall University School of Law, 2020; B.A., Lehigh University, 
summa cum laude, 2017.  I would like to thank Professor Tara Ragone for her guidance in 
the writing of this Comment.  I would also like to thank my family, fiancé, and friends for 
their unwavering love and support throughout my entire law school career.  
 1  “Opioids are a class of drugs that act in the nervous system to produce feelings of 
pleasure and pain relief.”  Common examples are heroin and legally prescribed narcotic 
medications to manage severe and chronic pain conditions.  Opioid Addiction, GENETICS 
HOME REFERENCE – U.S. NAT’L LIBRARY OF MED. (Nov. 2017), https://ghr.nlm.nih.gov/cond 
ition/opioid-addiction.  
 2  See Understanding the Epidemic, CTR. FOR DISEASE CONTROL AND PREVENTION 
(Aug. 30, 2017), https://www.cdc.gov/drugoverdose/epidemic/index.html.   
 3  Prescription Opioid Data - Overview, CTR. FOR DISEASE CONTROL AND PREVENTION 
(Aug. 30, 2017), https://www.cdc.gov/drugoverdose/data/prescribing/overview.html 
[hereinafter Prescription Opioid Data]. 
 4  Rebecca Ahrnsbrak, Jonaki Bose, Sarra L. Hedden, Rachel N. Lipari, & Eunice 
Park-Lee, Key Substance Use and Mental Health Indicators in the United States: Results 
from the 2016 National Survey on Drug Use and Health fig.27, SUBSTANCE ABUSE AND 
MENTAL HEALTH SERV. ADMIN. (2017), https://www.samhsa.gov/data/sites/default/files/NS 
DUH-FFR1-2016/NSDUH-FFR1-2016.htm#opioid. 
 5  The Opioid Crisis, THE WHITE HOUSE, https://www.whitehouse.gov/opioids/ (last 
visited Oct. 23, 2019).   
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While the effects of this opioid epidemic on individuals and their 
families are the predominant focus of media attention,6 the effects of the 
opioid crisis on the local workplace and the national economy are also 
significant.7  In fact, a 2017 report by the Council of Economic Advisers 
(the “CEA”)8 estimated that the opioid crisis reduced workforce 
productivity by over $20 billion in 2015.9  Thus, employers are 
undoubtedly feeling the impacts of the opioid crisis, and this Comment 
urges employers to exercise caution in the policies they adopt in 
confronting the crisis. 
In the midst of the current opioid epidemic, employers could be 
tempted to engage in rigid, inflexible, and even knee-jerk reactions when 
they discover that a job applicant or employee is either taking opioid 
medication or has a history of opioid misuse or abuse.  Given the 
declaration of the opioid epidemic as a national public health emergency 
and the heightened media attention surrounding opioid use, employers 
might wish to immediately take adverse action against such an employee to 
insulate themselves from any potential problems arising from the opioid 
use.  Such short-sighted conduct would actually expose the employer to 
considerable legal liability.  This Comment aims to help employers 
navigate through potential legal pitfalls while attempting to minimize the 
effects of the opioid crisis in their own workplace.  It also recommends 
positive solutions that can aid employers in realizing that goal.  This 
Comment therefore asserts that employers must be wary of the potential 
minefield of taking adverse actions against employees for their past or 
present opioid use—barring current illicit use—without legal justification, 
and instead, encourages employers to become part of the solution to 
combatting this crisis. 
Part II of this Comment describes the opioid epidemic’s specific 
effects on both the workplace and the U.S. economy, demonstrating its 
grave effects in the employment context.  Part III discusses how the 
 
 6  See, e.g., Erin Schumaker, Here’s How the New Opioid Deal Could Help Kids and 
Families, HUFFINGTON POST (Oct. 24, 2018), https://www.huffingtonpost.com/entry/new-
opioid-deal-kids-families_us_5bbcc11ae4b0876edaa26021. 
 7  See Dan Mangan, Economic Cost of the Opioid Crisis: $1 Trillion and Growing 
Faster, CNBC (Feb. 13, 2018),  
https://www.cnbc.com/2018/02/12/economic-cost-of-the-opioid-crisis-1-trillion-and-
growing-faster.html.  
 8  The CEA is a United States agency within the Executive Office of the President 
charged with offering the President objective economic advice on the formulation of both 
domestic and international economic policy.  Council of Economic Advisers, THE WHITE 
HOUSE, https://www.whitehouse.gov/cea/(last visited Sept. 29, 2019). 
 9  The Underestimated Cost of the Opioid Crisis, THE COUNCIL OF ECON. ADVISERS 1 
(Nov. 2017), https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Under 
estimated%20Cost%20of%20the%20Opioid%20Crisis.pdf [hereinafter 2017 CEA Report]. 
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Americans with Disabilities Act (the “ADA”) and state anti-discrimination 
laws provide substantial protections to employees who are either past 
(illicit or otherwise) or present legal opiate users.  It is therefore crucial for 
employers to understand which actual or potential employees are covered 
under the ADA and their own state’s anti-discrimination laws regarding 
opioid use and the legal protections afforded to their employees.  Part IV 
recommends that employers exercise caution in drafting new drug policies 
or confirm that their existing policies are ADA compliant.  Part IV also 
explains how employers often use their drug policies as justification for 
adverse employment actions against employees and how such drug policies 
might be significant sources of litigation and legal exposure if not drafted 
correctly.  For instance, employers must be particularly wary of the “drug-
free workplace” label and the drug testing procedures contained in their 
policies.  Part V encourages employers to take a proactive approach and 
recognize the substantial impact they can have in confronting the opioid 
epidemic.  It makes recommendations to employers regarding possible 
support systems to implement, thereby cultivating good will with their 
employees and reducing the likelihood that the epidemic’s negative effects 
will seep into their workplace.  Finally, Part VI provides a brief conclusion 
of the Comment’s analysis. 
II. EVALUATING THE EFFECTS OF THE OPIOID CRISIS IN THE EMPLOYMENT 
CONTEXT 
On October 24, 2018, President Trump signed the Substance Use-
Disorder Prevention that Promotes Opioid Recovery and Treatment for 
Patients and Communities Act—also known as the SUPPORT for Patients 
and Communities Act (the “Act”)—into law.10  Recognizing the magnitude 
of the opioid crisis affecting the country, the final version of this legislation 
passed in the Senate with a remarkably bipartisan, 98 to 1, vote on October 
3, 2018.11  Apart from “[t]he most high-profile aspects of the bipartisan bill 
deal[ing] directly with the [opioids],”12 the Act also includes provisions 
discussing the opioid epidemic’s effect on children and families.13  For 
example, the Act includes provisions supporting residential treatment 
facilities where children can stay with their parents receiving substance use 
 
 10  Marianna Sotomayor, Trump Signs Sweeping Opioid Bill with Vow to End ‘Scourge’ 
of Drug Addiction, NBC NEWS (Oct. 24, 2018), https://www.nbcnews.com/politics/congress 
/trump-signs-sweeping-opioid-bill-vow-end-scourge-drug-addiction-n923976. 
 11  Colby Itkowitz, Senate Easily Passes Sweeping Opioid Legislation, Sending to 
President Trump, WASH. POST (Oct. 3, 2018), https://www.washingtonpost.com/politics/201 
8/10/03/senate-is-poised-send-sweeping-opioids-legislation-president-trump/?utm_term=.06 
b83d99b5a5. 
 12  Schumaker, supra note 6.  
 13  Id. 
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disorder treatment instead of going into the foster care system and adopts 
plans outlining care for infants with neonatal opioid exposure.14  The Act 
also includes a section “addressing economic and workforce impacts of the 
opioid crisis.”15  Section 8401 outlines a pilot program that authorizes the 
Secretary of Labor to make $100 million in grants per fiscal year to state 
workforce agencies, which can in turn make subgrants to local workforce 
development boards to address the economic and workplace effects of the 
opioid crisis.16  Section 8401, however, is just one relatively short section 
in an immense piece of legislation and was not included in the mainstream 
media’s coverage of the bill’s signing.17  Finding ways to assist individuals 
and families struggling with substance use disorder is deservedly at the 
forefront of conversations surrounding the opioid epidemic, so it is no 
surprise that the epidemic’s effect in the employment arena is not as 
frequently considered.  The opioid crisis, however, is also having severe 
negative impacts on the U.S. economy and the employment sector as a 
whole. 
According to a report issued by Altarum, a “nonprofit health research 
and consulting institute,”18 the opioid epidemic’s economic cost in the U.S. 
from 2001 to 2017 exceeded $1 trillion.19  The report also projected that the 
opioid crisis would cost the U.S. economy an additional $500 billion by 
2020.20  As the CEA described in its November 2017 report, the “nonfatal 
costs” of the opioid epidemic, such as healthcare, criminal justice, and 
employment costs, are significant.21  For example, in 2013 alone, 
prescription opioid abuse resulted in approximately $28 billion in 
 
 14  Id.  
 15  SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. § 8041 (2018).  
 16  Id.  
 17  See, e.g., John Fritze & David Jackson, What’s Included in the Opioids Bill Signed 
by President Trump, USA TODAY (Oct. 24, 2018), https://www.usatoday.com/story/news/po 
litics/2018/10/24/donald-trump-opioids-bill-includes-changes-trafficking-treatment/175232 
9002/; Sarah Owermohle, Trump to Sign Sweeping Bill, POLITICO (Oct. 24, 2018), 
https://www.politico.com/newsletters/politico-pulse/2018/10/24/trump-to-sign-sweeping-
opioid-bill-386557; Itkowitz, supra note 11; Sotomayor, supra note 10.  
 18   Economic Toll of Opioid Crisis in U.S. Exceeded $1 Trillion Since 2001, ALTARUM 
(Feb. 13, 2018), https://altarum.org/news/economic-toll-opioid-crisis-us-exceeded-1-trillion-
2001.  
 19  Id. See also Greg Allen, Cost of U.S. Opioid Epidemic Since 2001 is $1 Trillion and 
Climbing, NPR (Feb. 13, 2018), https://www.npr.org/sections/health-shots/2018/02/13/5851 
99746/cost-of-u-s-opioid-epidemic-since-2001-is-1-trillion-and-climbing; Tom Valentino, 
Opioid Crisis Now $1 Trillion Problem, BEHAV. HEALTHCARE EXECUTIVE EXEC. (Feb. 13, 
2018), https://www.behavioral.net/article/prescription-drug-abuse/opioid-crisis-now-1-trillio 
n-problem. 
 20  ALTARAM, supra note 18. 
 21  See 2017 CEA Report, supra note 9, at 8.  
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healthcare and substance use disorder treatment costs,22 $7.5 billion in 
criminal justice costs,23 and over $20 billion in reduced productivity 
costs.24  Critical to note in assessing the opioid epidemic’s costs to 
economic productivity is the fact that most deaths resulting from opioid 
overdoses in the U.S. in 2015 occurred among individuals ranging between 
twenty-five and fifty-five years old—prime working age.25  Given the 
unfortunate fact that most of the opioid epidemic fatalities are resulting in 
the loss of prime-working-age individuals, it comes as no surprise that the 
American labor-force participation rate, which calculates the percentage of 
Americans either employed or actively seeking work, hovered between 
62.7% and 63.1% in both 201726 and 201827—low by historical standards.28  
For example, between 1986 and 2009, the labor force participation rate 
consistently fell between 65% and 67%.29  Alan Krueger, a Princeton 
economist, has conducted a study showing “a striking relationship between 
these missing workers and increasing opioid addiction”30 and has 
concluded that “over the past fifteen years, labor-force participation among 
prime-age workers has declined the most in U.S. counties where opioid 
prescriptions are the most plentiful.”31  While it is difficult to establish 
whether the increased rate in opioid prescriptions is causing the lower labor 
force numbers or whether the lower labor force numbers are resulting in 
increased opioid prescriptions, Krueger explains that “[r]egardless of the 
direction of causality, the opioid crisis and depressed labor force 
 
 22  Curtis Florence, Feijun Luo, Likang Xu, & Chao Zhou, The Economic Burden of 
Prescription Opioid Overdose, Abuse and Dependence in the United States, 2013, NAT’L 
CTR. FOR INJURY PREVENTION AND CONTROL, CTR. FOR DISEASE CONTROL AND PREVENTION 
1, 13 (Oct. 2016), https://stacks.cdc.gov/view/cdc/55377.  
 23  Id.  
 24  Id.  
 25  See 2017 CEA Report, supra note 9, at 5.  
 26  Gillian B. White, The Opioid Crisis Comes to the Workplace, THE ATLANTIC (Dec. 
21, 2017), https://www.theatlantic.com/business/archive/2017/12/workers-dying-
overdoses/549008/. 
 27  United States Labor Force Participation Rate, TRADING ECONOMICS, 
https://tradingeconomics.com/united-states/labor-force-participation-rate (click calendar 
visual beneath the chart and insert “2018-01-01” and “2018-12-31” to view 2018 labor force 
participation rate data) (last visited Sept. 29, 2019). 
 28  See White, supra note 26; see U.S. DEP’T OF LABOR, BUREAU OF LABOR STATISTICS, 
CIVILIAN LABOR FORCE PARTICIPATION RATE, https://www.bls.gov/charts/employment-
situation/civilian-labor-force-participation-rate.htm (last visited Sept. 10, 2019).  
 29  Id.  
 30  See White, supra note 26. 
 31  Id. See also Alan B. Krueger, Where Have All the Workers Gone? An Inquiry Into 
the Decline of the U.S. Labor Force Participation Rate, BROOKINGS 48–49 (Sept. 7, 2017) 
https://www.brookings.edu/bpea-articles/where-have-all-the-workers-gone-an-inquiry-into-
the-decline-of-the-u-s-labor-force-participation-rate/ (analyzing the growth of opiod 
prescription use as a factor in the decrease of labor force participation).  
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participation are now intertwined in many parts of the United States.”32 
Additionally, employers not only face a reduced labor force, but face 
opiate-related issues with their existing employees as well.  According to a 
2017 National Safety Council survey, 70% of employers with fifty or more 
employees have experienced workplace incidents due to prescription drug 
use.33  More specifically, 39% of those employers cited that they have dealt 
with employee absenteeism and 29% claimed to have experienced 
employees’ impaired or decreased job performance because of prescription 
drug use.34  Succinctly stated, employers are dealing with real challenges to 
the national workforce and economy, in addition to direct effects within 
their own workplaces, because of the current opioid crisis. 
III. ANTI-DISCRIMINATION PROTECTIONS OFFERED BY THE AMERICAN 
WITH DISABILITIES ACT 
Employers experiencing the direct effects of the current opioid 
epidemic must be aware of how to properly treat opioid-using employees 
and how to recognize, evaluate, or characterize misuse and abuse.  
Employers unsure of how to deal with the opioid epidemic might be 
tempted to draft blanket policies forbidding all opiate use, thereby failing 
to distinguish between an employee’s legal use and abuse.  Part IV 
describes some cases in which employers have utilized and attempted to 
enforce such blanket policies, ultimately exposing themselves to litigation 
that could have been avoided had they remained ADA-compliant.  It is true 
that “[h]istorically, an employee’s drug use in violation of a ‘drug free 
workplace’ policy almost surely meant termination,”35 but that no longer 
remains the case today.  Ultimately, employers considering taking adverse 
employment action against an opioid-using employee must be careful to 
ensure that they are not punishing legal opiate use (such as employees 
taking opioid medications to treat “moderate-to-severe pain, after surgery 
or injury, or pain from health conditions like cancer”)36 and that the 
employee is not a member of a protected class under the ADA and/or their 
own state’s anti-discrimination laws.  It is therefore critical for employers 
to have a firm grasp on the employee protections afforded to opioid users 
under both the ADA and existing state law.  This section will explain who 
 
 32  See Krueger, supra note 31, at 55.  
 33  How the Prescription Drug Crisis is Impacting American Employers, NAT’L SAFETY 
COUNCIL 1, 6, 8 (2017), https://www.nsc.org/Portals/0/Documents/NewsDocuments/2017/M 
edia-Briefing-National-Employer-Drug-Survey-Results.pdf [hereinafter 2017 NSC Report]. 
 34  Id. at 8. 
 35  Benjamin E. Widener, Opioid Accommodation: Overview, Case Study and 
Recommendations, N.J.L.J. (Aug. 10, 2018, 10:00 AM), https://www.law.com/njlawjournal/ 
2018/08/10/opioid-accommodation-overview-case-study-and-recommendations/. 
 36  See Prescription Opioid Data, supra note 3. 
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qualifies as a disabled individual entitled to ADA protections and what 
protections the ADA offers to those individuals.  It will then apply both of 
those concepts more narrowly to the opioid use context. 
A. An Introduction to the American with Disabilities Act in the 
Employment Context 
The ADA was passed by Congress in 1990 “to provide a clear and 
comprehensive national mandate for the elimination of discrimination 
against individuals with disabilities; [and] to provide clear, strong, 
consistent, enforceable standards addressing discrimination against 
individuals with disabilities.”37  The ADA defines “employers” as persons 
engaged in commercial industries with fifteen or more employees.38  It 
further mandates that employers “shall [not] discriminate against a 
qualified individual on the basis of disability in regard to job application 
procedures [or] the hiring, advancement, or discharge of employees . . . .”39  
In order to fully understand which employees are protected by this ADA 
mandate in the opioid context, it is first necessary to further define 
“disability” and “qualified individual[s].” 
1. Defining Covered Disabilities 
The ADA defines “disability . . . with respect to an individual” as “(i) 
[a] physical or mental impairment that substantially limits one or more of 
the major life activities of such individual; (ii) [a] record of such 
impairment; or (iii) [b]eing regarded as having such impairment.”40  Thus, 
employees can qualify as disabled under the ADA through any of the 
preceding three definitions—the “actual disability” prong, the “record of” 
prong, or the “regarded as” prong. 
In the opioid context, the “actual disability” prong could, for example, 
include an employee who is suffering from opioid addiction as the result of 
taking legally prescribed opiate medications.41  The addiction could be 
either the physical and/or mental impairment that substantially limits one or 
more of the employee’s major life activities, such as caring for oneself, 
communicating, interacting with others, and working.42  A non-addicted 
employee taking legally-prescribed opiates could also qualify under the 
“actual disability prong” because the underlying medical condition (such as 
 
 37  Americans with Disabilities Act of 1990, 42 U.S.C. § 12101(b)(1)–(2). 
 38  42 U.S.C. § 12111(2), (5)(A) (1990). 
 39  Id. at § 12112(a). 
 40  29 C.F.R. § 1630.2(g)(1)(i)–(iii) (2019). 
 41  Id. at § 1630.2(h)(1)–(2).  
 42  Id. at § 1630.2(i)(i). 
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cancer)43 requiring the use of those opiates will typically qualify as the 
physical or mental impairment impeding an individual’s major life 
activities required to satisfy the ADA’s definition of a disability.44  
Moreover, the ADA Amendments Act of 2008 mandates that the definition 
of disability is meant to be read broadly45 and instructs that “the question of 
whether an individual’s impairment is a disability under the ADA should 
not demand extensive analysis.”46  Employers should be aware, therefore, 
that it will not be difficult for an employee taking opioid medications to 
successfully argue that he or she has an “actual disability.” 
The “record of” prong in the opioid context could include an 
employee with a record of past drug addiction and/or drug treatment and 
rehabilitation programs.47  Assuming the employee has overcome their 
addiction and no longer has an “actual disability,” the employee would still 
have a record of a physical or mental impairment—the prior addiction—
that substantially limited one or more of their major life activities.48 
The ADA deems an employee disabled under the “regarded as” prong, 
even if they do not have, or never have had, a physical or mental 
impairment that substantially limits one or more of their major life 
activities, if the employer perceives them as having such impairment.49  
Thus, an employee could be deemed disabled under the ADA if an 
employer regards an employee as being addicted to opioids, regardless of 
whether that perception is correct, and regardless of whether that employee 
actually uses opiates or not.50 
2. Defining Qualified Individuals and Their Rights Under the 
ADA 
The ADA does not permit employers to discriminate against “a 
qualified individual” on the basis of any of the three preceding definitions 
of disability.  Importantly, a “qualified individual” is someone who can 
perform the essential functions of their job, with or without reasonable 
accommodation.51  In the opioid context, it is important to note that an 
employee or job applicant who is currently engaging in the illegal use of 
 
 43  See Prescription Opioid Data, supra note 3.  
 44  29 C.F.R. § 1630.2(g)(1)(i).  
 45  Elisa Y. Lee, Note, An American Way of Life: Prescription Drug Use in the 
American Workplace, 45 COLUM. J.L. & SOC. PROBS. 303, 321 (2011). 
 46  ADA Amendments Act of 2008, 110 P.L. 325, 122 Stat. 3553, § 2(b)(5). 
 47  29 C.F.R. § 1630.2(k)(1). 
 48  Id. at §1630.2(k)(2). 
 49  Id. at § 1630(l)(1). 
 50  Id.  
 51  42 U.S.C. § 12111(8) (2018). 
CAMPISI-FORMATTED (DO NOT DELETE) 11/15/2019  7:25 PM 
2019] COMMENT 567 
drugs is not considered a qualified individual.52  As a result, employers are 
free to take adverse employment actions without fear of consequences 
stemming from employee’s current illegal drug use.53 
Notably, the Equal Employment Opportunity Commission (EEOC) 
has defined “current illegal drug” use as having “occurred recently enough 
to justify an employer’s reasonable belief that involvement with drugs is an 
ongoing problem.”54  Furthermore, an employee who tests positive on a 
drug test will also be considered a current illegal drug user.55 
On the other hand, the ADA specifies that employees who have 
completed a drug rehabilitation program and are no longer using illegal 
drugs,56 employees who are currently enrolled in a drug rehabilitation 
program but are no longer using illegal drugs,57 and those who are 
erroneously regarded as using illegal drugs58 are qualified individuals 
entitled to ADA protection.  Moreover, qualified individuals include those 
taking opioid medications legally prescribed by a healthcare professional.59  
If an individual were to become addicted to that opiate prescription 
medication while under the doctor’s care, they would still be protected 
under the ADA because the use of the prescription drugs as directed is not 
illegal.60  Individuals who utilize prescription medications in ways other 
than prescribed, however, would be considered engaged in the 
aforementioned current illegal use of drugs.61 
These definitions of legal and illegal drug use notably leave a lapse in 
ADA protection for employees who relapse while receiving treatment.  
While “[t]he chronic nature of addiction means that for some people 
relapse . . . can be part of the process . . . and relapse doesn’t mean 
treatment has failed,”62 the ADA is clear that only those “who have 
 
 52  Id. at § 12114(a). 
 53  Id.  
 54  U.S. EQUAL EMP’T OPPORTUNITY COMM’N, EEOC-M1A, A TECHNICAL ASSISTANCE 
MANUAL ON THE EMPLOYMENT PROVISIONS (TITLE I) OF THE AMERICANS WITH DISABILITIES 
ACT § 8.3 (1992) [hereinafter EEOC MANUAL].  
 55  Id.  
 56  42 U.S.C. § 12114(b)(1). 
 57  Id. at § 12114(b)(2). 
 58  Id. at § 12114(b)(3). See also 29 CFR § 1630.2(g)(1)(iii). 
 59  42 U.S.C. § 12111(6)(A). 
 60  LEGAL ACTION CENTER, Questions and Answers from Webinar: Know Your Rights: 
Employment Discrimination Against People with Alcohol/Drug Histories, SUBSTANCE 
ABUSE AND MENTAL HEALTH SERV. ADMIN. 2, https://www.samhsa.gov/sites/default/files/pa 
rtnersforrecovery/docs/QA_Employment_Discrimination.pdf (last visited September 29, 
2019). 
 61  Id.  
 62  Drugs, Brains, and Behavior: The Science of Addiction, Treatment and Recovery, 
NAT’L INST. ON DRUG ABUSE (July 2018), https://www.drugabuse.gov/publications/drugs-
brains-behavior-science-addiction/treatment-recovery [hereinafter Drugs, Brains, and 
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completed a drug rehabilitation program and are no longer using illegal 
drugs”63 or those “who are currently enrolled in a drug rehabilitation 
program but are no longer using illegal drugs”64 are entitled to protection.  
Thus, even an employee who is actively participating in treatment will be 
deemed to have engaged in current illegal drug use if they have a positive 
drug test.65  A similarly-situated employee could also be deemed to have 
engaged in current illegal drug use if they suffer a relapse that could justify 
an employer’s reasonable belief that involvement with drugs is an ongoing 
problem.66  Such employer determinations are made on a case-by-case 
basis.67 
Despite this somewhat expansive definition of “current illegal drug 
use,” it should be noted that individuals currently participating in 
medication-assisted treatments (MAT) are also qualified individuals subject 
to the protections of the ADA.68  MAT utilizes controlled substances such 
as methadone and buprenorphine to treat opioid addiction both to short-
acting opioids, such as heroin, and synthetic opioids, such as prescription 
opiate drugs.69  MAT “normalize[s] brain chemistry, block[s] the euphoric 
effects of opioids, relieve[s] psychological cravings, and normalize[s] body 
functions,”70 allowing recipients to regain stable physical and 
psychological functioning.  Thus, although methadone and buprenorphine 
are actually opioids,71 MAT patients’ use of those substances is not 
considered illegal drug use; rather, it is considered part of a prescribed 
course of rehabilitative treatment.  By their very participation in MAT, 
employees will have a “record of” a disability—their opioid addiction—
and be “regarded as” having that disability.72  As a result, employees 
participating in MAT programs are qualified individuals entitled to ADA 
protection, as long as they are not also engaging in any current illegal drug 
use. 
Employers will be considered to have wrongfully discriminated 
against a qualified individual employee if they fail to make reasonable 
 
Behavior]. 
 63  42 U.S.C. § 12114(b)(1) (emphasis added). 
 64  Id. at § 12114(b)(2) (emphasis added). 
 65  See EEOC MANUAL, supra note 54. 
 66  Id. 
 67  Id.  
 68  U.S. DEP’T OF HEALTH AND HUMAN SERV., SUBSTANCE ABUSE AND MENTAL HEALTH 
SERV. ADMIN., authored by LEGAL ACTION CENTER, HHS PUBLICATION NO. (SMA) 09-4449, 
KNOW YOUR RIGHTS: RIGHTS FOR INDIVIDUALS ON MEDICATION-ASSISTED TREATMENT 6 
(2009) [hereinafter KNOW YOUR RIGHTS].  
 69  Id. at 3.  
 70  Id. 
 71  See Drugs, Brains, and Behavior, supra note 62.   
 72  See KNOW YOUR RIGHTS, supra note 68, at 6–7.  
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accommodations for that employee73 or “deny employment opportunities to 
a job applicant or an advancement to a current employee based on the 
knowledge that they would have to make a reasonable accommodation for 
that employee.”74  Reasonable accommodations can consist of a variety of 
measures, such as restructuring some of the employee’s job responsibilities, 
permitting flexible work schedules or part-time work, or reassigning the 
employee to another vacant position.75  For example, adjusting work hours 
to allow an employee no longer engaging in current illegal drug use to seek 
treatment and rehabilitative services could constitute a reasonable 
accommodation. 
3. Concluding Anti-Discrimination Protections 
Before taking any adverse employment action against an employee on 
the basis of their drug use, employers must protect themselves from 
liability by ensuring that the employee is not a qualified individual with a 
qualifying disability under the ADA, or, if the employee is a qualified 
individual, that the employee could not be afforded a reasonable 
accommodation. 
Employers should also be aware of the anti-discrimination laws 
adopted by their own states.  With the exception of Alabama,76 every state 
has a general anti-discrimination statute that protects employees from 
discrimination on the basis of disability or handicap.77  The majority of 
these state laws against discrimination in employment include categories of 
employers that are not regulated by the ADA, such as state or public 
employers and employers with fewer than fifteen employees.78 
B. Options for Employers Wanting to Take Adverse Employment 
Action Against a Disabled Employee 
While employers must ensure compliance with the ADA and its state 
equivalents, they are not without recourse if they wish to take adverse 
employment action against an employee with an ADA-recognized 
 
 73  42 U.S.C. § 12112(b)(5)(A) (2018). 
 74  Id. at § 12112(b)(5)(B). 
 75  Id. at. § 12111(9)(B). 
 76  Alabama does not have a general anti-discrimination statute but does require state 
and state-funded employers to employ “the blind, the visually handicapped and the 
otherwise physically disabled . . . on the same terms and conditions as the able-bodied, 
unless it is shown that the particular disability prevents the performance of the work 
involved.”  ALA. CODE § 21-7-8; State Employment-Related Discrimination Statutes, NAT’L 
CONF. OF STATE LEGISLATURES 1 (July 2015), http://www.ncsl.org/documents/employ/Discr 
imination-Chart-2015.pdf. 
 77  State Employment-Related Discrimination Statutes, supra note 76. 
 78  Id. 
CAMPISI-FORMATTED (DO NOT DELETE) 11/15/2019  7:25 PM 
570 SETON HALL LAW REVIEW [Vol. 50:559 
disability.  Consider the following scenario: A laborer for a twenty-
employee construction company is taking opioid medications for acute 
chronic back pain.  His back pain has led him to request that he only work 
three days a week, but his employer needs someone for five days and 
cannot afford to bring on an additional employee.  The side effects from his 
opioid medications inhibit his ability to operate machinery necessary to 
perform his job.  This section will explain what options the ADA affords 
employers in such situations. 
It is first necessary to note that employers do not have to make a 
reasonable accommodation for a disabled job applicant or employee if they 
“can demonstrate that the accommodation would impose an undue hardship 
on the operation of the[ir] business.”79  An undue hardship in this context is 
defined as an accommodation requiring significant difficulty or expense for 
the employer.80  In evaluating whether an accommodation would constitute 
an undue hardship for the employer, the ADA instructs that the following 
factors must be considered: (1) the accommodation’s nature and cost; (2) 
the financial resources of the facility providing the accommodation and the 
accommodation’s impact upon facility operations; (3) the employer’s 
overall financial resources; and (4) the type of employer operation.81  
Essentially, employers are not required to make an accommodation for a 
disabled employee if it is beyond the employer’s means, financial or 
otherwise.82  Specific to the scenario above, the construction company 
should attempt to make a reasonable accommodation by allowing the 
laborer to work only three days a week and attempting to find someone to 
cover the other two days.  If, however, that was not possible (for example, 
the employer’s financial state was such that it could not pay both the new 
laborer working five days a week and the original laborer working three 
days a week), paying both employees could impose an undue hardship on 
the construction company, who would then not be required to honor the 
original laborer’s request.  Whether an employer would experience a 
legitimate undue hardship and truly could not afford to make any 
reasonable accommodation for a disabled employee is ultimately a fact-
sensitive, case-by-case inquiry.83 
Furthermore, the ADA only protects employees to the extent that their 
legal opioid use is not negatively affecting their job performance.  Recall 
 
 79  42 U.S.C. § 12112(b)(5)(A).   
 80  42 U.S.C. § 12111(10)(A). 
 81  Id. at § 12111(10)(B).  
 82  Id. at § 12111(10)(A).  
 83  What Is Considered an “Undue Hardship” For a Reasonable Accommodation?, 
ADA NAT’L NETWORK, https://adata.org/faq/what-considered-undue-hardship-reasonable-
accommodation. 
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that a “qualified individual” for ADA protection is one “who, with or 
without reasonable accommodation, can perform the essential functions of 
the employment position.”84  What constitutes “essential functions” of a job 
is a fact-sensitive inquiry, but the ADA provides some deference to the 
employer’s judgment, especially in the presence of a written job 
description.85  For example, if an employee was legitimately no longer able 
to perform the essential functions of their job because of their legally-
prescribed opioid medication’s side effects, an employer could be within its 
rights to terminate that employee.  It is true that even the use of legally-
prescribed opiates is not without risk; common side effects of opioids 
include dizziness, nausea, vomiting, and physical dependence.86  These 
risks could undoubtedly affect job performance in some employees. 
Employers are not, however, entitled to complete deference in 
determining whether a particular function is essential to a job.  Aside from 
an employer’s judgment about the essentiality of a job function, “[w]ritten 
job descriptions prepared before interviewing applicants for the job; the 
amount of time spent performing the function; consequences of not 
requiring the incumbent to perform the function; terms of a collective 
bargaining agreement; work experience of past incumbents; and/or current 
work experience of incumbents in similar jobs”87 should also be 
considered.  Furthermore, all determinations of whether a function is 
essential to a job have to take place on a case-by-case basis.88  Ultimately, 
the EEOC explained that courts “are not intended to second guess an 
employer’s business judgment” in the determination of what constitutes a 
job’s essential functions.89  But to best protect the interests of their 
qualified individual employee and protect themselves from legal liability, 
employers still must evaluate the employee’s ability to perform the job on 
an individualized, case-by-case basis, and should consider the other 
aforementioned factors of what constitutes an essential job function. 
Returning to the earlier hypothetical, if operating machinery is a clear 
essential function of the employee’s job, but the employee cannot do so 
because of the side effects of his legally-prescribed opioid medication, the 
employer should document the inability of that employee to perform an 
 
 84  42 U.S.C. § 12111(8) (emphasis added). 
 85  See Lee, supra note 45, at 322–23.   
 86  See Ramsin Benyamin et al., Opioid Complications and Side Effects, PAIN 
PHYSICIAN 11:S105 (2008), http://www.painphysicianjournal.com/current/pdf?article=OTg1 
&journal=42. 
 87  29 C.F.R. § 1630.2(n)(3)(ii)–(vii) (2019).  
 88  Procedures for Providing Reasonable Accommodation for Individuals with 
Disabilities, U.S. EQUAL EMP’T OPPORTUNITY COMM’N, https://www.eeoc.gov/eeoc/internal/ 
reasonable_accommodation.cfm (last visited Feb. 9, 2019).  
 89  See Lee, supra note 45, at 322–23. 
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essential job function and could potentially fire the employee.  Before 
choosing to ultimately terminate that employee, however, the employer 
must also consider potential reasonable accommodation alternatives, such 
as restructuring the employee’s job responsibilities or reassigning the 
employee to another vacant position, in order to maximize its insulation 
from potential legal liability.90 
In summary, employers must have a comprehensive understanding of 
the protections extended to disabled employees under the ADA.  
Employers are not, however, without recourse if the employee cannot 
perform the essential functions of their job, even with a reasonable 
accommodation, or if such reasonable accommodation would cause an 
undue hardship to the employer.91 
IV. THE NEED TO EXERCISE CAUTION IN DRAFTING DRUG POLICIES 
Now armed with a greater understanding of the ADA as it pertains to 
employment discrimination in the opioid context, this section emphasizes 
that employers (and their lawyers) have to exercise caution and flexibility 
in drafting and revising their workplace drug policies in order to avoid 
legal exposure arising out of an employee’s opioid use.  It will first 
describe how employers must utilize care and precision when labeling 
themselves as a “drug-free workplace,” so as not to punish employees’ 
legal opiate use in violation of the ADA.  This section will then utilize case 
law to demonstrate how failure to use such care has resulted in legal action 
and subsequent liability against employers.  Finally, it will also discuss 
how drug testing and medical inquiry sections of employer drug policies 
also need to be drafted with precision in order to avoid violating 
employees’ ADA-protected rights and prevent legal exposure for 
employers. 
A. An Introduction to the “Drug-Free Workplace” Label 
As Part IV.B. will illustrate, in light of the current opioid epidemic, 
employers might be inclined to take action against their opiate-using 
employees, even when the opiates are legally prescribed, to avoid potential 
workplace problems.  One method they might consider employing is a 
“drug-free workplace” policy.  A “drug-free workplace” sounds good in 
theory, but employers must be wary of it in practice.  Employers have been 
subject to lawsuits and subsequent liability because they have made 
adverse employment decisions against employees engaged in legal drug use 
in the name of their “drug-free workplace” policies. 
 
 90  See 42 U.S.C. § 12111(9)(B) (2018). 
 91  Id. at § 12111(8).  
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The “drug-free workplace” label is utilized by the federal government 
in certain contexts92 and is encouraged by multiple states.93  The Federal 
Drug-Free Workplace Act was passed by Congress in 1988 and stipulates 
that federal contractors and federal grant recipients must provide a drug-
free workplace by engaging in various steps, including “publishing a 
statement notifying employees that the unlawful manufacture, distribution, 
dispensation, possession, or use of a controlled substance is prohibited in 
the grantee’s workplace and specifying the actions that will be taken 
against employees for violations of the prohibition.”94  Multiple state 
legislatures have cited their intent to promote drug-free workplaces so that 
employers “may be afforded the opportunity to maximize their levels of 
productivity, enhance their competitive positions in the marketplace, and 
reach their desired levels of success without experiencing the costs, delays, 
and tragedies associated with work-related accidents resulting from drug or 
alcohol abuse by employees.”95  In fact, state legislatures are providing 
incentives to employers to enact drug-free workplace policies, including 
offering reductions in employers’ worker’s compensation premiums96 or, as 
in the federal Drug-Free Workplace Act, conditioning state grants and 
contracts on the grantee employer having a drug-free workplace policy 
barring illicit drugs from the workplace.97 
The main issue with drug-free workplace policies is that employers 
must be wary of the fact that their prohibitions may, inadvertently or 
otherwise, extend to legally-prescribed drugs.  The federal Drug-Free 
Workplace Act and state analogs specify that they apply only to unlawful 
or illegal drug use or drug-related activity.  If not drafted carefully, drug-
free workplace policies can lead to unwarranted discrimination against 
individuals who can still safely and capably perform their jobs while taking 
legally-prescribed drugs.98  Moreover, “the use of any particular 
prescription drug, despite its side-effect warnings, is generally a poor 
indicator of employee risk” by itself.99  Essentially, employers should not 
assume that employees might pose a potential risk of problems arising in 
 
 92  See Drug-Free Workplace Act, 41 U.S.C. § 8101(a)(5) (2018). 
 93  U.S. DEP’T OF LABOR, 50 STATE SURVEY: DRUG-FREE WORKPLACE PROGRAMS (Sept. 
1, 2009), http://www.lexisnexis.com/documents/pdf/20090930094905_large.pdf. See, e.g., 
FLA. STAT. ANN. § 112.0455; IOWA CODE § 730.5; OHIO ADMIN. CODE § 4123-17-58. 
 94  41 U.S.C.S. § 8102(a)(1)(A); 41 U.S.C.S. § 8103(a)(1)(A) (emphasis added). 
 95  ARK. CODE ANN. § 11-14-101. See also GA. CODE ANN. § 34-9-410; TENN. CODE 
ANN. § 50-9-101. 
 96  ALA. CODE § 25-5-332; GA CODE ANN. § 34-9-412; IDAHO CODE § 72-1716. 
 97  30 ILL. COMP. STAT. ANN. 580/3; S.C. CODE. ANN. § 44-107-30; VA. CODE ANN. § 
2.2-4312. 
 98  See Lee, supra note 45, at 337–38. 
 99  Id. at 338. 
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the workplace on the basis of their legal opiate use. 
It is critical that employers realize that they can easily insulate 
themselves from legal liability and remain compliant with the ADA by 
prohibiting only illegal drug use and activity in their drug-free workplace 
policies.  If employers have concerns about an employee’s use of legally-
prescribed opiate medications negatively affecting their ability to 
adequately perform their particular job, employers must take action after a 
legitimate individualized evaluation, rather than relying solely upon a 
blanket drug-free workplace policy.100 
B. Case Law Illustrations of Why Employers Should Not Enact 
Blanket Drug-Free Workplace Policies 
Case law is instructive in understanding the significance of the 
liability risks associated with drug-free workplace policies and how to 
avoid them.  The following cases will explain various circumstances in 
which blind adherence to drug-free workplace policies has led to liability 
exposure for employers and reinforce the need to ensure that such policies 
make the legally necessary accommodations for an employee’s legal opioid 
use. 
1. Huffman v. Turner Industries Group, LLC 
Huffman v. Turner Industries Group, LLC outlines a set of 
circumstances in which an employer took adverse action against an 
employee taking a legally-prescribed opioid medication because of the 
employer’s blanket drug-free workplace policy.  The employer incurred 
significant legal fees and costs, while exposing itself to potential liability, 
by blindly enforcing its policy prohibiting all opioids.  The employer failed 
to distinguish between legal and illegal drug use and acted on the blanket 
premise that even legal prescription drug use prevented the employee from 
performing his job, instead of conducting an individualized assessment of 
the employee’s ability to capably perform his job.  This case serves as a 
warning to employers taking adverse action against employees in the name 
of drug-free workplace policies instead of the employee’s work product. 
In 1986, Henry Huffman, a welder, lost part of his hand in a welding 
accident, and he took hydrocodone—an opioid pain medication—and 
Xanax—a benzodiazepine—to manage his persistent chronic pain in the 
aftermath.101  Between 2005 and 2011, Huffman had been intermittently 
hired by Defendant Turner Industries Group (Turner) to work part-time as a 
 
 100  Id. at 338–39. 
 101  Huffman v. Turner Indus. Grp., LLC, 2013 U.S. Dist. LEXIS 71842, at *2 (E.D. La. 
2013). 
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welder on various occasions.102  In September 2011, Huffman was offered a 
full-time job with Turner, contingent upon his successful completion of a 
drug screening and a physical examination with Turner’s contracted 
physician’s assistant.103  When Huffman told the physician’s assistant that 
he took hydrocodone—an opiate—three to four times a day, he was 
informed that such use was a violation of Turner’s “Drug, Alcohol, and 
Contraband Policy,” which required that “employees who work in safety-
sensitive positions, such as that of a welder, not take narcotic pain 
medications or benzodiazepines [anxiety medications] during working 
hours or within eight hours of reporting to work.”104  Although Huffman 
received a medical release from his physician stating that he required his 
pain pills three to four times daily, he was told by Turner representatives 
that he would still need to conform to their narcotic-free policy in order to 
work as a welder and ultimately was not hired.105  Subsequently, Huffman 
brought suit against Turner after receiving a right-to-sue letter from the 
Equal Employment Opportunity Commission.106 
Huffman alleged that he was not hired for full-time employment by 
Turner because he had a record of physical impairment and/or was 
regarded by Turner as having such impairment stemming from what he told 
the physician’s assistant about his legal opioid use—and thus was 
discriminated against on the basis of his disability.107  Huffman contended 
that the factual record “‘unequivocally establishe[d]’ that Turner did not 
base its employment decision on the kind of individualized and fact-
intensive assessment envisioned by the ADA, but on a ‘blanket “zero-
tolerance” policy,’ [assuming] that ‘any person who takes prescription 
narcotics, benzodiazepines, or muscle relaxers is too impaired to safely 
perform jobs at Turner.’”108  Turner filed a motion for summary 
judgment109 and maintained that Huffman could not establish a prima facie 
case of discrimination because he could not establish that the decision not 
to hire him was based on a record of disability or because Turner regarded 
him as disabled.110  Further, Turner argued that even if Huffman could 
establish a prima facie case, its drug policy served as an affirmative defense 
 
 102  Id. 
 103  Id. 
 104  Id.   
 105  Id. at *6.  
 106  Id. at *5–7. 
 107  Huffman, 2013 U.S Dist. LEXIS 71842, at *37–38. See also 29 C.F.R. § 
1630.2(g)(1)(ii)–(iii) (2019). 
 108  Huffman, 2013 U.S. Dist. LEXIS 71842, at *28. 
 109  Id. at *2. 
 110  Id. at *23–24. 
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because it “was both job-related and justified by business necessity.”111  
Turner admitted that although the side effects of opioid medications, such 
as drowsiness or dizziness, do not present themselves in everyone who 
takes them, “the possibility of their occurrence is always present and 
inherently dangerous when an individual performs a safety-sensitive task 
such as welding.”112  The United States District Court for the Eastern 
District of Louisiana denied Turner’s motion for summary judgment.113  
The court first established that Huffman satisfied the ADA’s definition of 
disability because he had a record of disability and because Turner 
regarded him as disabled.114  The court further found that Turner failed to 
hire Hoffman because of the opioid medication he used to manage his 
disability, thereby constituting sufficient evidence of a prima facie case of 
discrimination to defeat summary judgment.115  The court next denied 
Turner summary judgment on its affirmative defense of business 
necessity.116  The court noted: 
Plaintiff presents ample evidence that he performed the job of 
Welder for six years between 2005 and 2011 without incident, 
and, in fact, Turner notes that the ‘the only thing that changed 
between late 2005 when Plaintiff was first hired, and September 
16, 2011, when [he] was denied employment,’ was Plaintiff’s 
disclosure of his use of hydrocodone and Xanax during work 
hours.117 
Moreover, Huffman had produced a doctor’s evaluation stating that he did 
not experience any of the potential side effects of his medications.118 
Turner’s blanket drug policy, for all intents and purposes, made the 
company a drug-free workplace.  Turner understandably wanted to promote 
a safe environment, especially given the nature of some of the work 
conducted, such as welding.  In fact, Turner argued that the policy was 
written in response to some of its employees being “involved in industrial 
accidents at client job sites that were allegedly attributable to work-time 
use of narcotic pain medication by employees working in safety-sensitive 
positions.”119 
The side effects of legally-prescribed opiates are certainly real and can 
justifiably make employers nervous—especially those with employees 
 
 111  Id. at *25. 
 112  Id. at *26. 
 113  Id. at *23.  
 114  Huffman, 2013 U.S Dist. LEXIS 71842, at *39. 
 115  Id. at *39. 
 116  Id. at *52. 
 117  Id. at *40 (emphasis in original). 
 118  Id. at *50.   
 119  Id. at *2. 
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working in safety-sensitive positions.  Nonetheless, Huffman illustrates that 
blanket drug policies likely are an over-inclusive and unacceptable method 
of dealing with legal opioid use, and employers must realize that they can 
reach the same goals by simply conducting individualized assessments.  
Even from a pure financial standpoint, the extra time, effort, and cost to an 
employer of conducting individualized assessments is a worthwhile 
investment to avoid the very real possibility of much larger litigation costs 
and potential legal liability.  That type of legal exposure can lead to severe 
consequences for employers, as further evidenced in the next section. 
2. Stewart v. Snohomish County Public Utilities District No. 1 
Stewart v. Snohomish County Public Utilities District No. 1 also 
outlines the legal risk to employers of having a drug-free workplace policy 
that bans not only illicit drug use, but categorically prohibits all drug use, 
including the use of legally-prescribed medications.  This case also 
involves an employer who made a decision to terminate an employee for 
failing to adhere to its drug-free workplace policy without conducting an 
individualized assessment of the employee’s ability to perform her job.  
The ultimate outcome of this case reveals just how serious and expensive 
such a practice can be for employers. 
In Stewart, Plaintiff Stewart was a customer service representative of 
Defendant Snohomish County Public Utilities, an employer within the 
meaning of the Washington Law Against Discrimination, for over twenty 
years.120  Unfortunately, Stewart suffered from “chronic and debilitating” 
migraines.121  While she would attempt to treat her migraines with non-
narcotic medications, she also had to go to her doctor for injections of 
Dilaudid (hydromorphone)—an opiate—when the migraines would not 
subside.122  Stewart acquired intermittent medical leave under the Family 
and Medical Leave Act that allowed her to leave work for a few hours at a 
time to receive her injections, but her supervisors consistently gave her a 
difficult time for her absenteeism.123  Defendant had a “Fitness for Duty” 
policy prohibiting all employees from working under the influence of drugs 





 120  Stewart v. Snohomish Cty. Pub. Utils. Dist. No. 1, 262 F. Supp. 3d 1089, 1093 
(W.D. Wash. 2017). 
 121  Id. at 1094.  
 122  Id.  
 123  Id. at 1095. 
 124  Id. at 1094. 
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Stewart became upset after being confronted by a supervisor about her 
absence upon returning from an injection in October 2014.125  Her 
supervisors thought she was showing signs of impairment at work and 
drove her to be drug tested, informing her that she would be put on 
administrative leave while they “investigated her.”126  The drug test came 
back positive and, unsurprisingly, showed the presence of 
hydromorphone.127  In order to be permitted to return to work, Stewart 
signed a “Return to Work Agreement,” stating that she would be fired if 
she came to work while impaired.128  In April 2015, a few months after 
returning to work, Stewart had a similar experience to what had transpired 
in October 2014.129  After being driven to another drug test in which she, 
again, tested positive for hydromorphone, Stewart was terminated for 
violating the Fitness for Duty Policy and Return to Work Agreement by 
“coming to work while impaired.”130 
While the record made it difficult to ascertain whether Stewart was 
actually impaired on the days of the October 2014 and April 2015 
incidents, or simply upset by the way she was being treated by her 
employer, the court found that Defendant “ha[d] not shown that any 
impairment prevented Stewart from properly performing her job [on either] 
day.”131  As a result, the court determined that Stewart had a disability that 
could have been reasonably accommodated by Defendant, but Defendant 
“chose to address Stewart’s symptoms through a disciplinary process rather 
than an interactive one aimed at finding a reasonable accommodation that 
would allow Stewart to work and seek treatment for her disability.”132  The 
court further found that reasonable accommodations could have easily been 
made and that Defendant “could have treated her as an employee with a 
medical condition, rather than a drug abuser.”133  Because Defendant chose 
to terminate Plaintiff based upon violations of its blanket drug prohibition 
policy—which made no exceptions for legal drug use—instead of making 
reasonable accommodation efforts, the court awarded Plaintiff over $1.8 
million in damages.134 
Stewart is a cautionary tale that warns employers, in drafting their 
drug policies, against adopting a policy that blindly imposes blanket 
 
 125  See id. at 1096. 
 126  See Stewart, 262 F. Supp. 3d at 1097. 
 127  See id. 
 128  See id. at 1098–99.  
 129  See id. at 1100–01. 
 130  See id. at 1101–02. 
 131  Id. at 1097, 1101. 
 132  See Stewart, 262 F. Supp. 3d at 1105.  
 133  Id. at 1106. 
 134  See id. at 1113. 
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prohibitions on all drug use.135  Whether the “drug-free workplace” label is 
specifically used in the language of the policy or not, employers (and their 
lawyers) must recognize that it is illegal to create drug-free workplaces 
that, in effect, do not accommodate the legal use of opiate medications. 
C. Employers Must Carefully Craft the Drug Testing and Medical 
Inquiry Components of their Drug Policies to Protect Themselves 
from Liability 
Employers have the right to drug test and make medical inquiries of 
job applicants and employees, but only at specific times and under specific 
circumstances.136  Employers are permitted to require their job applicants 
and employees to undergo illegal drug testing, as well as make employment 
decisions as a result of those tests.137  In order to best protect themselves 
from liability and to give future or current employees reasonable notice that 
consequences may follow for certain actions, an employer’s drug policy 
should be explicit in describing when and under what circumstances the 
employer may require a drug test or conduct a drug-related medical 
inquiry.  As a matter of best practices, the policy should also clearly 
describe what consequences an employee can expect if they have a positive 
drug test. 
Employers can also make medical inquiries of current or prospective 
employees in order to ascertain their ability to do the job, but must be wary 
of the various ADA guidelines in place to ensure that such inquiries are not 
being used to wrongfully discriminate against employees.  These ADA 
guidelines “reflect Congress’s intent to protect the rights of applicants and 
employees to be assessed on merit alone, while protecting the rights of 
employers to ensure that individuals in the workplace can efficiently 
perform the essential functions of their jobs.”138 
Notably, the ADA guidelines distinguish permitted medical inquiries 
on the basis of whether the qualified individual is a job applicant, has 
already received an offer of employment, or is a current employee.139  Prior 
to making an offer of employment to a job applicant, employers cannot 
“conduct a medical examination or make inquiries of a job applicant as to 
 
 135  See generally Stewart, 262 F. Supp. 3d at 1089.  
 136  See 42 U.S.C. § 12114(d) (2018) (explaining that a test for illegal drugs shall not be 
considered a medical examination); 42 U.S.C. §12112(d) (setting forth the limited 
circumstances in which employers can make a medical examination or inquiry).   
 137  See 42 U.S.C. §§ 12114(d)(1)–(2). 
 138  See generally Enforcement Guidance: Disability-Related Inquiries and Medical 
Examinations of Employees Under the Americans with Disabilities Act (ADA), U.S. EQUAL 
EMP’T OPPORTUNITY COMM’N (July 27, 2000), https://www.eeoc.gov/policy/docs/guidance-
inquiries.html#N_5_. 
 139  See 42 U.S.C. § 12112(d)(2)–(4).  
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whether such applicant is an individual with a disability or as to the nature 
or severity of such disability,”140 but they can ask about “the ability of an 
applicant to perform job-related functions.”141  Once an offer of 
employment has been made, employers can condition that offer on 
successful completion of a medical examination, as long as that is the 
standard procedure for all entering employees.142  Once a person is 
officially an employee, employers may conduct voluntary medical 
examinations and inquire into the ability of the employee to perform job-
related functions.143  Employers cannot require a current employee to 
undergo a medical examination and “shall not make inquiries of an 
employee as to whether such employee is an individual with a disability or 
as to the nature or severity of the disability, unless such examination or 
inquiry is shown to be job-related and consistent with business 
necessity.”144 
Despite these ADA guidelines, case law demonstrates that sometimes 
employers’ drug policies or medical inquiries are overly broad and 
intrusive into an employee’s legal drug use, thereby leaving that employer 
susceptible to legal claims. 
1. Harrison v. Benchmark Electrics of Huntsville, Inc. and 
Medical Inquiries of Job Applicants 
In Harrison v. Benchmark Elecs. Huntsville, Inc., Plaintiff, a 
temporary worker for the Defendant, applied for a full-time position at the 
request of his supervisor.145  After testing positive for barbiturates during 
the application process, his supervisor called him into his office to speak 
over the phone with a Medical Review Officer.146  The supervisor did not 
leave the room, however, when Plaintiff answered the Medical Review 
Officer’s questions regarding his private medical information, such as the 
fact that he had suffered from epilepsy since he was an infant, took the 
barbiturates to control the condition, and revealed his dosage amounts.147  
The supervisor subsequently told the human resources department not to 
extend a job offer to the Plaintiff.148  The Eleventh Circuit reversed the 
District Court’s grant of summary judgment to the Defendant, finding that 
the ADA prohibits medical inquiries “as to whether such applicant is an 
 
 140  42 U.S.C. § 12112(d)(2)(A). 
 141  Id. at § 12112(d)(2)(B). 
 142  See id. at § 12112(d)(3)(A). 
 143  See id. at § 12112(d)(4)(B). 
 144  See id. at § 12112 (d)(4)(A). 
 145  See 593 F.3d 1206, 1209 (11th Cir. 2010). 
 146  See id. at 1210. 
 147  See id. 
 148  See id. 
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individual with a disability or as to the nature or severity of such 
disability”149 before an offer of employment is made.  The Eleventh Circuit 
further held that “a reasonable jury could infer that the supervisor’s 
presence in the room was an intentional attempt likely to elicit information 
about a disability in violation of the ADA’s prohibition against pre-
employment medical inquiries.”150  Thus, if Plaintiff had already been an 
employee at the time of his positive drug test, the employer could have 
undertaken a medical inquiry without fear of liability as long as it was job-
related and consistent with business necessity.  Because the Plaintiff was 
still only a job applicant, however, the Defendant was not within its legal 
rights to attempt any inquiry into the Plaintiff’s disability status. 
2. Roe v. Cheyenne Mountain Conference Resort and Medical 
Inquiries of Current Employees 
In Roe v. Cheyenne Mountain Conference Resort, Defendant 
Cheyenne Mountain Conference Resort developed a new Drug and Alcohol 
Testing Policy which Plaintiff,  a current employee, refused to consent to, 
citing its requirements as unreasonable and intrusive.151  Plaintiff brought 
the action to enjoin its implementation.152  The employer’s drug policy at 
issue read: “[e]mployees must report without qualification, all drugs 
present within their body system.  Further, they must remain free of drugs 
while on the job . . . .  Additionally, prescribed drugs may be used only to 
the extent that they have been reported and approved by an employee 
supervisor . . . .”153  The United States District Court for the District of 
Colorado held that this prescription drug disclosure provision violated the 
ADA, a decision that was upheld by the Tenth Circuit Court of Appeals 
even though other aspects of the case were reversed and remanded.154  The 
District Court found that the prescription drug disclosure provision at issue 
violated section 12112(d)(4)(A) of the ADA,155 which provides that an 
employer cannot require medical examinations or make inquiries of an 
employee’s disability “unless such examination or inquiry is shown to be 
job-related and consistent with business necessity.”156  Since the Defendant 
failed to make any such showing, the District Court held, and the Tenth 
Circuit affirmed, that the drug policy violated the “plain language” of the 
 
 149  42 U.S.C. § 12112(d)(2)(A).  
 150  Harrison, 593 F.3d at 1216. 
 151  See Roe v. Cheyenne Mt. Conf. Resort, 124 F.3d 1221, 1226 (10th Cir. 1997). 
 152  See id. 
 153  Id. (emphasis removed). 
 154  See id. at 1231. 
 155  See Roe v. Cheyenne Mt. Conf. Resort, 920 F. Supp. 1153, 1155 (D. Colo. 1996).   
 156  42 U.S.C. § 12112(d)(4)(A) (2018). 
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ADA.157  Thus, the employer left itself open to potential liability by 
requiring in its policy that employees report all drug use without showing 
that such inquiry was job-related and consistent with business necessity, in 
direct violation of the ADA’s protections for legal drug users. 
D. Conclusions on Drug Policies 
While many employers have existing policies regarding drug use in 
the workplace, it is imperative that employers understand that they: (1) 
cannot impose a blanket “drug-free workplace” policy without exposing 
themselves to significant legal ramifications; and (2) must differentiate 
between illegal drug use, which is not permitted, and legal drug use, which 
may be permitted.  Including prohibitions on legal drug use in drug policies 
and taking adverse action against an employee or job applicant because of 
such use leaves the employer open to unnecessary liability.  As 
demonstrated by the $1.8 million award to the plaintiff in Stewart,158 that 
liability can be quite costly. 
Further, employers should ensure that any drug testing and medical 
inquiry provisions of their drug policies are compliant with the ADA’s 
various guidelines about when such testing and inquiries are permitted.  In 
so doing, employers will protect the rights of their employees, who deserve 
to be free from worry of disability status discrimination and to be judged on 
the basis of the merits of their job performance.  Simultaneously, 
employers will be reducing their own legal exposure by ensuring that any 
adverse action that is taken against an employee in accordance with their 
drug policies will be compliant with ADA regulations. 
V.  RECOMMENDATIONS FOR SUPPORTING EMPLOYEES 
Part III explained that employers have a legal obligation to remain 
compliant with federal and state anti-discrimination laws and ensure that 
they do not wrongfully discriminate against job applicants or employees 
engaged in legal prescription opiate use.159  But, as a policy matter, 
employers’ roles can and should expand far beyond simply ensuring their 
compliance with anti-discrimination employment regulations.  In fact, 
employers can take proactive steps towards combatting the opioid epidemic 
to achieve a twofold purpose: providing valuable assistance to employees 
and protecting employers from legal liability by offering their employees 
support before problems related to opioid use, or even abuse, arise. 
 
 157  Roe, 920 F. Supp. at 1155. 
 158  Stewart v. Snohomish Cty. Pub. Utils. Dist. No. 1, 262 F. Supp. 3d 1089, 1113 
(W.D. Wash. 2017). 
 159  See Parts III.A., Part IV.B.  
CAMPISI-FORMATTED (DO NOT DELETE) 11/15/2019  7:25 PM 
2019] COMMENT 583 
Fortunately, many employers have shown a willingness to take a more 
active role in providing assistance to their employees during the opioid 
crisis.  According to a National Safety Council survey about the effect of 
prescription drugs upon employers, 70% percent of employers said they 
would like to help employees struggling with prescription drug misuse or 
abuse, and 48% percent responded that they would return the employee to 
their position after appropriate treatment.160  Such help is critical, according 
to Deborah Hersman, the president and CEO of the National Safety 
Council, because “[r]esearch indicates that those struggling with substance 
abuse have better sustained recovery rates if their employers help them to 
receive treatment and monitor their recovery, than if treatment is initiated 
by family or friends[.]”161 
A. Employers May Be Able to Negotiate Alternative Pain Treatment 
Coverage with Health Insurance Companies 
Opioids are commonly prescribed as pain medications.  “In recent 
years, there has been a dramatic increase in the acceptance and use of 
prescription opioids for the treatment of chronic, non-cancer pain, such as 
back pain or osteoarthritis, despite serious risks and the lack of evidence 
about their long-term effectiveness.”162  In fact, “[t]he amount of opioids 
prescribed and sold in the United States has quadrupled since 1999, but the 
overall amount of pain reported by Americans hasn’t changed.”163  Since 
health care providers started prescribing more opioids for pain management 
in the late 1990s,164 the risks of these medications have manifested more so 
than the rewards.  Unfortunately, as many as one in four patients receiving 
legally-prescribed opioid therapy struggle with addiction.165  Thus, while 
the availability of opioid pain medications remains an important option for 
patients—in fact, for some patients, a necessary and indispensable one166—
 
 160  See 2017 NSC Report, supra note 33, at 16.  
 161  Stephen Miller, As Opioid Epidemic Rages, Worksite Policies Overlook Prescribed 
Drugs, SOC’Y FOR HUMAN RES. MGMT. (Mar. 17, 2017), https://www.shrm.org/resourcesand 
tools/hr-topics/benefits/pages/workplace-rx-drug-policies.aspx. 
 162  Prescription Opioids, CTR. FOR DISEASE CONTROL AND PREVENTION (Aug. 29, 2017), 
https://www.cdc.gov/drugoverdose/opioids/prescribed.html. 
 163  CDC Guideline for Prescribing Opioids for Chronic Pain, CTR. FOR DISEASE 
CONTROL AND PREVENTION https://www.cdc.gov/drugoverdose/pdf/guidelines_at-a-glance-
a.pdf (last visited Sept. 29, 2019).  
 164  Opioid Overdose Crisis, NAT’L INST. ON DRUG ABUSE (Mar. 2008), 
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis. 
 165  Prescription Opioids - Addiction and Overdose, CTR. FOR DISEASE CONTROL AND 
PREVENTION (Aug. 29, 2017), https://www.cdc.gov/drugoverdose/opioids/prescribed.html. 
 166  See, e.g., Will Stone, Patients with Chronic Pain Feel Caught in an Opioid-
Prescribing Debate, KAISER HEALTH NEWS (Aug. 1, 2018), https://khn.org/news/patients-
with-chronic-pain-feel-caught-in-an-opioid-prescribing-debate/.  
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health care providers have also been encouraged to start evaluating 
alternative pain treatment options.167  These alternative pain treatment 
options can include, among others, acupuncture, physical therapy, 
cognitive behavioral therapy, yoga, and chiropractic treatment.168 
State Medicaid agencies have already made an effort to cover 
alternative pain treatments that can be used instead of opioids when 
appropriate.169  As of the most recent data from the Henry J. Kaiser Family 
Foundation, which tracks Medicaid benefits offered by the states, all but six 
states reimburse providers for at least one category of alternative pain 
treatment, including physical therapy, occupational therapy, and 
chiropractic services.170  In a 2016 survey conducted by the National 
Academy for State Health Policy, twelve states said that their Medicaid 
agency “implemented specific policies or programs to encourage or require 
alternative pain management strategies in lieu of opioids for acute or 
chronic non-cancer pain.”171 
Similarly, private employers, individually or in conjunction with other 
private employers, may be able to negotiate with their health insurers for 
pain management treatments that could serve as an alternative to opioids.  
Such treatments have shown efficacy in reducing pain172 without the risk of 
tolerance or addiction presented by opioids.  These treatments provide 
patients with safer pain management alternatives, thereby reducing the risk 
of impairment occurring at work and potential conflicts between the 
employer and employee arising from such impairments.  By providing 
employees with the ability to utilize alternative pain treatments in cases 
where their conditions are not so severe as to necessitate the use of opioids, 
employers can play an important role in reducing the number of employees 
who turn to opioids for pain management (and the corresponding risk of 
 
 167  See generally Deborah Dowell, Tamara M. Haegerich, & Roger Chou, CDC 
Guideline for Prescribing Opioids for Chronic Pain – United States, 2016, CTR. FOR 
DISEASE CONTROL AND PREVENTION MORBIDITY AND MORTALITY WEEKLY REPORT 16 (Mar. 
18, 2016), https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf. 
 168  Dean Drosnes, Chronic Pain Management: There Are Alternatives to Opioids, 
CARON (Mar. 7, 2018), https://www.caron.org/blog/2018/03/chronic-pain-management-
alternatives-to-opioids; Dawn J. Lanouette, Opioid Addiction Enters the Workplace, AM. 
BAR ASS’N SECTION OF LITIG., THE WOMAN ADVOCATE (Mar. 14, 2018), https://www.ameri 
canbar.org/groups/litigation/committees/woman-advocate/articles/2018/opiate-addiction-
workplace.html. 
 169  Hannah Dorr & Charles Townley, Chronic Pain Management Therapies in 
Medicaid: Policy Considerations for Non-Pharmacological Alternatives to Opioids, NAT’L 
ACAD. FOR ST. HEALTH POL’Y 1 (Aug. 2016), https://nashp.org/wp-content/uploads/2016/09/ 
Pain-Brief.pdf. 
 170  Id. at 4. 
 171  Id. 
 172  See Drosnes, supra note 168. 
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addiction), thereby limiting the negative impacts of opioid use in the 
workplace.  In doing so, employers would offer a valuable benefit to their 
employees, and at the same time, lower the risk of a potential liability 
arising from opioid use in the workplace. 
B. Employers Must Comply with the Family and Medical Leave Act 
Regulations as They Relate to Substance Use Disorder. 
The Family and Medical Leave Act (the “FMLA”) allows eligible 
employees of a covered employer to take job-protected leave (paid or 
unpaid depending on the circumstances) for up to twelve weeks per year 
“because the employee is needed to care for a family member with a 
serious health condition [or] because the employee’s own serious health 
condition makes the employee unable to perform the functions of his or her 
job . . . .”173  Generally, an eligible employee “has been employed for a 
total of at least [twelve] months by the employer on the date on which any 
FMLA leave is to commence,”174 and covered employers are those 
engaging in commerce who employ fifty or more employees.175 
Substance use disorder can qualify as a serious health condition, 
providing that it requires inpatient care or continuing treatment by a 
healthcare provider.176  An employee can only take FMLA leave for 
continuing treatment by a healthcare provider, however, upon health care 
provider referral.177  Employers cannot take adverse action against an 
employee taking FMLA leave to care for a family member receiving 
substance use disorder treatment.178  Upon completion of FMLA leave, an 
employee is entitled to return to either the same position or an equivalent 
position.179 
Because employees taking leave to care for a family member suffering 
from substance use disorder are fully protected against any adverse 
employment actions by the FMLA,180 it is prudent for employers to offer 
their support for their caregiver employees by quickly and amiably granting 
FMLA leave when it is requested.  By displaying understanding and 
keeping the employee’s job or an equivalent position ready for their return, 
employers can offer comfort to employees during troubling times and 
 
 173  29 C.F.R. § 825.100(a) (2019). 
 174  Id. at § 825.102. 
 175  Id. at § 825.104(a). 
 176  Id. at § 825.119(a).  For further explanation of the intricacies of what constitutes 
“continuing treatment by a healthcare provider,” see 29 C.F.R. §825.115.  
 177  Id. at § 825.119(a).  
 178  Id. at § 825.119(b). 
 179  29 C.F.R. § 825.100(c). 
 180  Id. at § 825.119(b). 
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prevent exposure to future liability at the same time. 
Employees can take leave to receive treatment for substance use 
disorder, but an employee’s absence from work resulting from that 
employee’s use of a substance such as opiates is not covered under the 
FMLA.181  Put more simply, employers can grant an employee FMLA 
leave to obtain substance use disorder treatment.  But, if an employee does 
not show up at work one day because of their substance use, the employee 
cannot then go back and ask for that day they missed to be covered under 
FMLA leave. 
Furthermore, employers cannot take adverse action against an 
employee for taking FMLA leave to obtain substance use disorder 
treatment.  That does not, however, mean that an employee is protected 
against all adverse actions stemming from substance use.  If an employer 
has an “established policy, applied in a non-discriminatory manner that has 
been communicated to all employees, that provides under certain 
circumstances an employee may be terminated for substance abuse, 
pursuant to that policy the employee may be terminated whether or not the 
employee is presently taking FMLA leave.”182  In other terms, if an 
employer has a clear policy that stipulates that employees may be 
terminated for substance use disorder under certain circumstances, and this 
policy applies to and is communicated to all employees, the fact that the 
employee is now on FMLA leave seeking treatment for substance use 
disorder does not prevent the employer from taking adverse action.  Such a 
policy would still, however, remain subject to aforementioned ADA 
requirements.  Employers cannot take adverse action against an employee 
for their legal drug use, so they must ensure that this policy permitting 
termination of employees for “substance abuse” would only apply to an 
employee’s current, illegal drug use. 
C. Employers May Promote a Work Environment Where Employees 
Know About and are Not Afraid to Seek Out Their Company’s 
Employee Assistance Program. 
“An employee assistance program is a work-based intervention 
program designed to assist employees in resolving personal problems that 
may be adversely affecting the employee’s performance.”183  Larger 
employers will likely have an employee assistance program for employees 
to utilize.  Over 97% of companies with more than 5,000 employees, 80% 
 
 181  Id. at § 825.119(a). 
 182  Id. at § 825.119(b). 
 183  General: What is an Employee Assistance Program (EAP)?, SOC’Y FOR HUM. RES. 
MGMT. https://www.shrm.org/resourcesandtools/tools-and-samples/hr-qa/pages/whatisaneap 
.aspx (last visited Sept. 29, 2019). 
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of companies with 1,001 to 5,000 employees, and 75% of companies with 
251 to 1,000 employees have employee assistance programs.184  An 
employee assistance program can help an employee struggling with opiate 
misuse or abuse by “offer[ing] counseling and referral services; 
conduct[ing] substance abuse evaluations[,] connect[ing] an employee to a 
qualified substance abuse professional . . . [and monitoring an] employee’s 
participat[ing] in, and compliance with treatment as well as return-to-work 
recommendations.”185 
Employers with employee assistance programs should play a more 
active role in promoting their services to employees.  Despite the large 
percentage of companies with employee assistance programs, the national 
average of employees who utilize them is only 3%.186  Some employees 
might not even know that employee assistance programs are available to 
them.187  Employees have also expressed confidentiality concerns about 
information getting back to employers.188  Therefore, employers can create 
more productive workplaces by proactively encouraging their employees to 
utilize employee assistance programs when necessary and assuring them 
that those services are confidential in accordance with Health Insurance 
Portability and Accountability Act of 1996 (HIPPA) regulations.189  Such a 
policy allows employers to help employees nip a potential opioid abuse 
problem in the bud and/or assist employees in obtaining the appropriate 
treatment. 
VI. CONCLUSION 
As the U.S. confronts the opioid national public health emergency, 
employers might find themselves navigating through some murky waters.  
Employers should ensure that they have carefully-drafted drug policies that 
both promote a productive work environment for their employees and 
shield themselves from potential liability.  Drug policies should specify, 
and enforce, prohibitions on illegal drug use in the workplace.  In the 
context of legal drug use, however, adverse action against an employee 
 
 184  Frequently Asked Questions, INT’L EMP. ASSISTANCE PROF’L ASS’N, 
http://www.eapassn.org/faqs (last visited Sept. 29, 2019). 
 185  How Employee Assistance Programs Can Address Opioid Painkiller Abuse and 
Addiction, NAT’L SAFETY COUNCIL (2014), https://www.nsc.org/Portals/0/Documents/RxDr 
ugOverdoseDocuments/RxKit/EMP-How-Employee-Assistance-Programs-can-Address-
Painkiller-Abuse-and-Addiction.pdf [hereinafter 2014 NSC Report]. 
 186  Id. 
 187  See Alia Hoyt, Why Hardly Anyone Uses Employee Assistance Programs, HOW 
STUFF WORKS (Aug. 22, 2017), https://money.howstuffworks.com/why-hardly-anyone-uses-
employee-assistance-programs.htm. 
 188  Id. 
 189  See 2014 NSC Report, supra note 185.  
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must only be based on legitimate, objective individual assessments of the 
employee’s inability to competently and safely perform the job (despite any 
reasonable accommodations made) rather than reliance on rigid “drug-free 
workplace” labels.  Following these guidelines reduces the chances of a 
lawsuit and minimizes, if not eliminates, legal liability should a disgruntled 
employee or former employee still choose to bring suit. 
Employers must ensure that their policies governing drug testing and 
medical inquiries are consistent with the different set of rules that apply to 
job applicants, those who have received a job offer, and current employees.  
Those policies should not be overly broad or intrusive as applied to an 
employee’s legal drug use.  Finally, employers should seek to surpass mere 
compliance with their drug policies and instead engage in proactive 
strategies offering supports to their employees.  Employers can take the 
initiative to negotiate for alternative pain management coverage in their 
offered health insurance plans and promote their employer assistance 
programs, as well as execute their legal obligation to allow employees to 
exercise their FMLA right to leave with compassion and understanding.  In 
doing so, employers can help to prevent opioid-related problems in the 
workplace before they begin, can support and foster goodwill with their 
employees, and further protect themselves from potential legal liability. 
 
